SAN DIEGO, Sept. 25, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released the latest episode of its Science Bytes podcast, featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros.

In Episode 51, Through the Shades of Illness, Testing Brings Clarity, Dr. O'Neil discusses how respiratory illnesses often present with overlapping symptoms, making it difficult to distinguish one condition from another without testing. Drawing on more than 20 years of emergency and urgent care experience, he explains how timely, accurate diagnostics not only guide treatment decisions but also protect families and communities from spread.
Key points from Dr. O'Neil's discussion include:
This episode highlights the vital role urgent care centers play in respiratory season by offering immediate access to testing and treatment when primary care or emergency departments may not be readily available.
The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$27.76 |
| Daily Change: | -0.06 -0.22 |
| Daily Volume: | 344,590 |
| Market Cap: | US$1.890B |
November 05, 2025 November 03, 2025 September 22, 2025 August 19, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load